Silence Therapeutics Launches New Video Game to Support International Thalassemia Day and Raise Disease Awareness

Silence Therapeutics Launches New Video Game to Support International Thalassemia Day and Raise Disease Awareness


  • Play the free online game and share your score on social #BloodRunBeta

  • Silence partners with Thalassaemia International Federation (TIF) to support May 8th awareness day activities – join the conversation on social media #ITD2021

4 May 2021

LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced the launch of a new, retro-inspired, online game to raise awareness of the rare blood disorder, thalassemia, ahead of International Thalassemia Day on Saturday May 8th 2021.

‘Blood Run Beta’ (www.bloodrunbeta.game) is a free game now available for people of all ages to play and learn more about the daily impact of thalassemia and one of its most common symptoms – fatigue. The aim of the game is to get as far as possible without the energy meter reaching zero, avoiding everyday obstacles that consume energy and ‘powering up’ by finding blood drops. The latter represent blood transfusions – one of the main treatment options for people with more severe forms of the disease. Everyone is encouraged to post their scores on social media using the hashtag #BloodRunBeta. By sharing the game on social media, Silence aims to draw public attention to this underrecognized community with high unmet need.

In addition, Silence is proud to be sponsoring the Thalassaemia International Federation (TIF)’s International Thalassemia Day (ITD) activities. ITD is a global event which takes place on May 8th each year, organized by TIF. It marks an opportunity for patient advocacy groups, charities, healthcare professionals, pharma/biotech companies and individuals around the world to unite in raising awareness of the condition through a variety of activities. The theme for this year is “Addressing Health Inequalities Across the Global Thalassemia Community” and the public can join in and show their support largely through social media, using the hashtag #ITD2021.

Giles Campion, MD, EVP, Head of R&D and Chief Medical Officer of Silence Therapeutics said:Thalassemia is a central focus of our research and while great strides have been made in recent years to raise awareness of the condition, there is still more that can be done. The burden of the disease and current treatment options that can be highly disruptive to daily life for patients and their families are often underrecognized. We are proud to partner with the thalassemia community and support better understanding of this often overlooked condition.”

Dr Androulla Eleftheriou (TIF Executive Director) of Thalassaemia International Federation said:
“International Thalassemia Day allows us to commemorate those who are no longer with us and to strengthen the efforts as well as commend those fighting for the right to a better quality of life and equal care across the globe. Increasing public awareness of the condition in new and creative ways is important as we expand our advocacy reach and put thalassemia on the health policy agenda of countries around the world. We are grateful to have partners like Silence who help us further our mission to support affected families on a global scale.”

Enquiries:

Silence Therapeutics plc

Gem Hopkins, Head of IR and Corporate Communications
[email protected]
Tel:  +1 (646) 637-3208
European PR

Consilium Strategic Communications

Mary-Jane Elliott/ Angela Gray / Chris Welsh
[email protected]

 

Tel: +44 (0) 20 3709 5700

About Thalassemia

Thalassemia is an inherited condition which prevents a person’s bone marrow from producing enough healthy red blood cells. Red blood cells carry oxygen from the lungs to all of the cells in the body to help them work normally. There are a number of different types of thalassemia, such as beta-thalassemia. The types vary from a very mild form to a severe disease that can be life-threatening if untreated. Current treatments can usually keep the symptoms under control do not treat the underlying cause of thalassemia or prevent it from progressing. Treatment to manage symptoms often requires regular hospital appointments that can disrupt normal life. More information about Thalassemia including quotes from patients about what it is like to live with the condition can be found here.

About Silence Therapeutics

Silence Therapeutics is developing a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence’s proprietary mRNAi GOLD™ platform can be used to create siRNAs that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence’s wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron loading anemias. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Takeda, among others. For more information, please visit https://www.silence-therapeutics.com/.

About TIF

The Thalassaemia International Federation (TIF) is a non-profit, non-governmental organization founded in 1986 by a small group of patients and parents. Its vision is to ensure equal access to quality health care for every patient with thalassemia and other hemoglobin disorders across the world, with a mission is to promote and implement national control programs for the prevention and treatment of thalassemia and other hemoglobin disorders in every affected country. TIF has a wealth of resources and provides links to local organizations around the world, to help patients or family members find support in their own country.  

Forward-Looking Statements

Certain statements made in this announcement are forward-looking statements, including with respect to the Company’s clinical development timeline and commercial prospects. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about its industry; its beliefs; and assumptions.  Words such as ‘anticipates,’ ‘expects,’ ‘intends,’ ‘plans,’ ‘believes,’ ‘seeks,’ ‘estimates,’ and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including the potential impact of COVID-19 on the Company’s clinical development and regulatory timelines and plans. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.



VBL Therapeutics to Report First Quarter Financial Results on May 11

TEL AVIV, Israel, May 04, 2021 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq: VBLT) will release its first quarter financial results for the period ended March 31, 2021 on Tuesday, May 11, 2021 before market open. Professor Dror Harats, M.D, Chief Executive Officer and Amos Ron, Chief Financial Officer, will host a conference call at 8:30am EDT the same day to discuss the results and provide a corporate update.

Conference Call:

Tuesday, May 11, 2021 at 8:30am EDT

Conference ID: 13719410
US: 1 877 407 9208
Israel Local: 1 809 406 247
International: 1 201 493 6784
Webcast: https://edge.media-server.com/mmc/p/w794ban7

About VBL

Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for areas of unmet need in cancer and immune/inflammatory indications. VBL has developed three platform technologies: a gene-therapy based technology for targeting newly formed blood vessels with focus on cancer, an antibody-based technology targeting MOSPD2 for anti-inflammatory and immuno-oncology applications, and the Lecinoxoids, a family of small-molecules for immune-related indications. VBL’s lead oncology product candidate, ofranergene obadenovec (VB-111), is an investigational, first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors. VB-111 is currently being studied in a VBL-sponsored Phase 3 registration enabling trial for platinum-resistant ovarian cancer.

CONTACT:

Burns McClellan for VBL Therapeutics

Lee Roth (investors) / Ryo Imai (media)
[email protected] / [email protected]
+1-212-213-0006



ProQR Therapeutics and Yarrow Biotechnology, an RTW Investments, LP Incubated Company, Announce Exclusive Worldwide License and Discovery Collaboration for Undisclosed Target

  • Yarrow
    Biotech
    nology, Inc.
    , a newly formed biotech
    nology
    company backed by RTW
    Investments, LP
    ,
    will
    lead development
    of
    the
    program
  • ProQR
    Therapeutics
    is eligible to receive
    upfront and milestone
    payments of up to $115 million
    plus
    royalties on future sales
    by
    Yarrow for an exclusive worldwide license and discovery collaboration on a non-ophthalmology target

NEW YORK, New York, LEIDEN, Netherlands & CAMBRIDGE, Mass., May 04, 2021 (GLOBE NEWSWIRE) —  RTW Investments, LP (“RTW”), a global, full life-cycle investment firm that focuses on identifying transformational and disruptive innovations across the biopharmaceutical and medical technologies sectors, and ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that Yarrow Biotechnology, Inc. (“Yarrow”) , a company newly created by RTW, has in-licensed exclusive rights to ProQR’s antisense oligonucleotide technology (ASO) to develop and commercialize potential therapies for an undisclosed non-ophthalmic target. Yarrow is focused on developing ASO-based therapeutics for disorders with high unmet need.

Roderick Wong, MD, Managing Partner and Chief Investment Officer of RTW, said: “We believe RNA-based therapies hold great promise to treat genetically-defined diseases. We are excited to partner with ProQR to in-license the first target to be developed in Yarrow’s pipeline.”

Under the terms of the agreement, ProQR is eligible to receive up to $115 million of upfront and milestone payments, plus single digit percentage royalties on the net sales of any resulting products during the royalty term. ProQR will also have the right to receive an undisclosed percentage of equity in the form of shares of common stock of Yarrow. ProQR will be responsible for certain preclinical activities with reimbursement for the research costs by Yarrow, while Yarrow will be responsible for continuing development of the program and commercialization activities.

Gerard Platenburg, Chief Innovation Officer at ProQR, will join Yarrow’s board of directors.

Peter Fong, PhD, Head of Company Creation at RTW, said: “Our partnership with ProQR fits perfectly into Yarrow’s mission to develop first-in-class ASO-based therapies for genetically-defined diseases. We look forward to a long and productive partnership.”

Daniel A. De Boer, Founder and CEO of ProQR, said: “As we focus ProQR on our core genetic eye disease strategy, we are pleased to partner with Yarrow to advance our technology in applications outside the eye, while generating value from this partnership and the broad applicability of our platform.”

About
RTW
Investments, LP

RTW Investments, LP (“RTW”) is a New York-based, global, full life-cycle investment firm that focuses on identifying transformational and disruptive innovations across the biopharmaceutical and medical technologies sectors. As a leading partner of industry and academia, RTW combines deep scientific expertise with a solution-oriented investment approach to support emerging medical therapies and the companies and academics developing them.

About
Yarrow
Biotechnology, Inc.

Yarrow Biotechnology, Inc. (“Yarrow”) is a newly formed biotechnology company developing antisense oligonucleotide-based therapeutics for disorders with high unmet need. Yarrow has established a proprietary target discovery engine leveraging large-scale human genetics studies to uncover novel targets where there is a significant unmet need.

Yarrow is the latest new company created and backed by RTW Investments, LP.

About ProQR

ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind. Learn more about ProQR at www.proqr.com.

Forward Looking Statements f
or ProQR

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to”, “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Such forward-looking statements include, but are not limited to, statements regarding the collaboration with RTW and Yarrow and the intended benefits thereof, including milestone and royalty payments from commercial product sales, if any, from the products covered by the collaboration and the issuance of equity in Yarrow to ProQR, as well as the potential of our technologies and product candidates. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. These risks and uncertainties include, among others, the cost, timing and results of preclinical studies and clinical trials and other development activities by us and our collaborative partners whose operations and activities may be slowed or halted by the COVID-19 pandemic; the likelihood of our clinical programs being executed on timelines provided and reliance on our contract research organizations and predictability of timely enrollment of subjects and patients to advance our clinical trials and maintain their own operations; our reliance on contract manufacturers to supply materials for research and development and the risk of supply interruption from a contract manufacturer; the potential for future data to alter initial and preliminary results of early-stage clinical trials; the unpredictability of the duration and results of the regulatory review of applications or clearances that are necessary to initiate and continue to advance and progress our clinical programs; the ability to secure, maintain and realize the intended benefits of collaborations with partners; the possible impairment of, inability to obtain, and costs to obtain intellectual property rights; possible safety or efficacy concerns that could emerge as new data are generated in research and development; and general business, operational, financial and accounting risks, and risks related to litigation and disputes with third parties. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

For
ProQR Therapeutics N.V.

Investor Contact:

Sarah Kiely
ProQR Therapeutics N.V.
T: +1 617 599 6228
[email protected]
or
Hans Vitzthum
LifeSci Advisors
T: +1 617 430 7578
[email protected]

Media Contact:

Cherilyn Cecchini, MD
LifeSci Communications
T: +1 646 876 5196
[email protected]

 



Sentient Energy® Adds 4X the Monitoring Capacity With New UM3+ Distribution Line Sensor for Underground Circuits, Now Able to Monitor up to Twelve Primary Power Cables

New multi-position UM3+ enables utilities with large underground grids to increase monitoring for greater visibility and control, while maximizing savings and efficiencies

FRISCO, Texas, May 04, 2021 (GLOBE NEWSWIRE) — Sentient Energy Inc., a Koch Engineered Solutions company and the leading provider of advanced grid monitoring and analytics for electric utilities, today announced the expansion of its UM3+ underground line sensor platform to support monitoring for up to four positions and twelve phases in a switchgear by simply adding an incremental plug-and-play component. This new modular design means utilities can monitor three, six, nine or twelve primary power cables with a single communications and processing unit, dramatically increasing efficiencies and savings while extending visibility and control to more lines at the grid edge.

Utilities often use a branching strategy for multiple primary cables within their underground cable system. Collecting performance data for monitoring and analyzing any faults or irregularities in these lines is essential for improving segmentation and reducing outage duration times. In these branched circuit scenarios, Sentient Energy’s multi-position UM3+ can monitor more than three and up to twelve phases to provide remote indication of which branch saw the fault, enabling faster repair and restoration.

The new multi-position UM3+ sensor installs inside a switchgear and collects data, which is then sent to the Sentient Energy platform where advanced grid analytics are performed to detect anomalies. In parallel, the data can also be sent to SCADA/DMS/OMS at the utilities’ control center. Utilizing one high-capacity sensor in each padmounted transformer, operators reduce the space required for sensors inside the transformer box. And remote indication of faults means operators can rest assured they will be restored faster, and the frequency and duration of outages will be minimized.

“Large utilities that have multiple branches in their distribution network need greater visibility and control of each line at the grid edge,” said Monika Murugesan, VP of Product Management at Sentient Energy. “With the new multi-position UM3+, operators can confidently monitor more lines from a single integrated sensor that detects, captures, analyzes, and alerts them about faults and non-fault disturbances. This increased capacity saves time, expense and adds efficiency to managing large networks of underground lines.”

Sentient Energy’s multi-position UM3+ is capable of cellular communication via most major cellular carriers. The solution also supports RF mesh network, or hybrid communications extending the reach of distribution line monitoring to include remote or rural areas.

About Sentient Energy

Sentient Energy, a Koch Engineered Solutions company, is the premier provider of intelligent sensing, data analytics, optimization, and control technologies for the distribution grid. Sentient Energy’s hardware and software solutions help electric utilities make data-driven decisions to enhance the delivery of reliable, safe, and efficient power. With the industry’s only Grid Analytics System that covers the entire distribution network, Sentient Energy leads the global market with the largest network of line sensor deployments in North America, gathering rich data in real time for predictive insights and strategic grid management. Sentient Energy’s Grid Edge ControlTM solutions enable utilities to reduce energy costs at the grid edge through Volt-VAR optimization, conservation voltage reduction, and peak demand reduction. Sentient Energy partners with leading communications network providers. For more information, visit www.sentient-energy.com.

Sentient Energy Media Contact:         
Andrea Cousens
[email protected]
310-270-8903 



Oncotelic Joins Chopra Foundation and Heart Foundation of India to Provide Relief for India’s Explosive 2nd Wave of Covid.

AGOURA HILLS, California, May 04, 2021 (GLOBE NEWSWIRE) — Oncotelic Therapeutics, Inc. (OTCQB:OTLC) (“Oncotelic”), a leading developer of TGF-β therapeutics for oncology and infectious disease and respiratory health will be working with Chopra Foundation and Heart Care Foundation to provide COVID-19 relief for India, including medicines and oxygen concentrators.

Medicines will include PulmoHeal, created by Oncotelic and our Indian partner – Windlas Biotech Pvt. Ltd. PulmoHeal is already available over-the-counter (OTC) in India on e-commerce platforms and pharmacies. PulmoHeal has been shown to improve long term respiratory recovery from COVID-19 and possibly from overuse of supplement oxygen- an area of unmet medical needs.

The deployment of PulmoHeal on a large scale will also enable the use of its Post Marketing Survey platform (PMS), which includes the cough artificial intelligence (AI) platform. Put together, PulmoHeal will enable the collection of data on the progression of patients’ response to COVID with its use, as well as other COVID medications. India is caught in a ferocious second wave of the coronavirus pandemic, with the Indian authorities reporting in excess of 400,000 new COVID-19 cases per day. Every one of these patients are participating in an uncontrolled clinical experimentation since there is no proven treatment protocol for COVID-19, except for dexamethasone. It is our objective to leverage our crowd source PMS platform to gather performance data across the multitude of experimental therapeutics being deployed on the Indian community such as Ivermectin, Vitamins, and Ayurvedic drugs. The goal is to arrive at definitive answer as to what is working and what is not working.

“Heart Care Foundation of India has been involved in providing free oxygen concentrators to those patients whose oxygen levels are dropping and who are not able to find a bed or resource in hospitals. This humanitarian deployment of PulmoHeal, together with oxygen, should be synergistic in both the immediate and long-term recovery of COVID-19 patients in India.” Said Saran Saund, Chief Business Officer, Oncotelic.

About the Chopra Foundation

The Chopra Foundation is a 501 (c) (3) organization dedicated to improving health and well-being, cultivating spiritual knowledge, expanding consciousness, and promoting world peace to all members of the human family. The mission of the Chopra Foundation is to advance the cause of mind/body spiritual healing, education, and research through fundraising for selected projects. https://www.choprafoundation.org/

Chopra Foundation is using the Go Fund Me platform to raise donations which will be deployed to the non-profit Heart Care Foundation of India (HCFI) to donate supplies like oxygen tanks and concentrators as well as medicine therapies to citizens in need. For more information, please go to: https://gofund.me/7706fe54

About Heart Care Foundation:

The Heart Care Foundation of India has been actively involved in literary activities as well as patient care since its inception and our efforts particularly gained pace during the Covid 19 pandemic as the need to educate and help more and more people was felt more than ever.

Dr KK Aggarwal, President Heart Care Foundation of India, undertook a mission to educate more than 1% of the population on digital platforms. More than 30 million viewers have been sensitized on COVID in 2021 alone through various social media channels. The Heart Care Foundation is running a 12hr free OPD on Zoom, with the meeting ID – 84290921517. We have a team of covid educators and doctors offering free consultation to almost 1000 patients daily for free. Over 1000 school principals and teachers have been trained as COVID guides. The Heart Care Foundation also trained 1000 health educators in 2020.

Regular update sessions are conducted on zoom to address the problems faced by patients daily as well by different experts. Heart Care Foundation of India has been involved in providing free oxygen concentrators to those patients whose oxygen levels are dropping and who are not able to find a bed or resource in hospitals. These oxygen concentrators are provided along with the treatment protocol which can be followed under the home management guidelines. The Heart Care Foundation is proud to announce this initiative saves- countless lives last year. This new wave of Covid 19 has been more deadly and dangerous and Heart Care Foundation of India has been on its toes to increase their resources to help the society at large

About
ARTIVeda



/
PulmoHeal


The product, ARTIVeda / PulmoHeal is a formulated plant extract of the indigenous plant Artemisia, known in Sanskrit texts as Damanaka. ARTIVeda / PulmoHeal is the first Ayurvedic drug against COVID-19 through TGF-β inhibition. ARTIVeda / PulmoHeal is expected to be effective through the entire infection cycle. The active component of ARTIVeda / PulmoHeal™ has been identified as artemisinin. Through proprietary GMP quality extraction and manufacturing processes, the Artemisia extract was rendered active against COVID-19 with robust Safety Index (SI) greater than 100 (ratio of nonspecific cell kill versus viral kill). Other extracts have SI <10. Testing was performed at the US NIAID core viral laboratory. ARTIVeda / PulmoHeal is protected by a patent portfolio of over 15 international patents by Oncotelic’s R&D. The mechanism of action against COVID-19 has been confirmed in 5 key peer reviewed international scientific/medical publications. ARTIVeda / PulmoHeal is designed to target multiple viral threats including COVID-19 by suppressing both viral replication and clinical symptoms that arise from viral infection. We have a product to be a cost effective prophylactic suitable for global deployment. For more information please visit www.pulmoheal.com.

About
Oncotelic

Oncotelic (formerly known as Mateon Therapeutics, Inc.) was created by the 2019 reverse merger with Oncotelic, which became a wholly owned subsidiary of Oncotelic, thereby creating an immuno-oncology company dedicated to the development of first in class RNA therapeutics as well as small molecule drugs against cancer and infectious diseases. OT-101, the lead immuno-oncology drug candidate of Oncotelic, is a first-in-class anti-TGF-βRNA therapeutic that exhibited single agent activity in some relapsed/refractory cancer patients in clinical trial settings. OT-101 also has shown activity against SARS-CoV-2 and COVID-19. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic has rare pediatric designation for DIPG (OT-101), melanoma (CA4P), and AML (OXi4503). For more information, please visit www.oncotelic.com and www.Oncotelic.com.

Oncotelic
‘s
Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as “may”, “expect”, “anticipate” “hope”, “vision”, “optimism”, “design”, “exciting”, “promising”, “will”, “conviction”, “estimate,” “intend,” “believe”, “quest for a cure of cancer”, “innovation-driven”, “paradigm-shift”, “high scientific merit”, “impact potential” and similar expressions are intended to identify forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about future plans, the progress, timing, clinical development, scope and success of future clinical trials, the reporting of clinical data for the company’s product candidates and the potential use of the company’s product candidates to treat various cancer indications. Each of these forward-looking statements involves risks and uncertainties and actual results may differ materially from these forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the company’s annual report on Form 10-K filed with the SEC on April 10, 2019 and in the company’s other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether as a result of new information future events, or otherwise.

Contact Information:

For Oncotelic Therapeutics, Inc.:
Amit Shah
[email protected]



Checkmate Pharmaceuticals Announces Initiation of Patient Dosing in Potential Registration Trial of Vidutolimod (CMP-001) in Patients with Anti-PD-1 Refractory Advanced Melanoma

CAMBRIDGE, Mass., May 04, 2021 (GLOBE NEWSWIRE) — Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that patient dosing was initiated in a Phase 2 trial intended to assess the efficacy and safety of vidutolimod (CMP-001) in combination with nivolumab for the treatment of patients with anti-PD-1 refractory advanced melanoma. Vidutolimod is an advanced generation Toll-like receptor 9 (TLR9) agonist, delivered as a biologic virus-like particle utilizing a CpG-A oligodeoxynucleotide as a key component. Checkmate previously announced initiation of dosing in patients in an additional trial which is evaluating the efficacy and safety of vidutolimod in combination with nivolumab compared to nivolumab monotherapy in patients with first-line metastatic or unresectable melanoma. The data from these two trials are intended to support a biologics license application for the treatment of patients with anti-PD-1 refractory advanced melanoma.

“Initiation of dosing in this pivotal trial is an important milestone as we move towards potential registration of vidutolimod in melanoma,” said Barry Labinger, President and Chief Executive Officer of Checkmate. “Melanoma is estimated to be the fifth most diagnosed cancer in the United States, with more than 100,000 new cases and 7,000 deaths per year. There is a significant unmet medical need for patients who have progressed following treatment with anti-PD-1 therapy since there is no well-established standard of care.”

Checkmate previously announced initiation of patient dosing in a Phase 2 trial of vidutolimod in combination with pembrolizumab to evaluate safety and efficacy in patients with first-line head and neck cancer.

Additional information about the Phase 2 anti-PD-1 refractory melanoma trial and the Phase 2/3 melanoma study, including participating investigative sites, can be found here: https://checkmatepharma.com/pipeline/clinical-trials/melanoma/.

Information about Checkmate’s HNSCC trial can be found here: https://checkmatepharma.com/pipeline/clinical-trials/head-and-neck-squamous-cell-carcinoma/.

About Checkmate Pharmaceuticals

Checkmate Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer. Checkmate Pharmaceuticals’ product candidate, vidutolimod (CMP-001), is an advanced generation Toll-like receptor 9 (TLR9) agonist, delivered as a biologic virus-like particle utilizing a CpG-A oligodeoxynucleotide as a key component, designed to trigger the body’s innate immune system to attack tumors in combination with other therapies. Information regarding Checkmate Pharmaceuticals is available at www.checkmatepharma.com.

Availability of Other Information About Checkmate Pharmaceuticals

Investors and others should note that we communicate with our investors and the public using our website (www.checkmatepharma.com), our investor relations website (ir.checkmatepharma.com), and on social media (Twitter and LinkedIn), including but not limited to: investor presentations and investor fact sheets, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Checkmate Pharmaceuticals posts on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in us to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Forward Looking Statements

Various statements in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including. Words such as, but not limited to, “anticipate,” “believe,” “can,” “could,” “expect,” “estimate,” “design,” “goal,” “intend,” “may,” “might,” “objective,” “plan,” “predict,” “project,” “target,” “likely,” “should,” “will,” and “would,” or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. These statements include those regarding our product candidate, including its development and therapeutic potential and the advancement of our clinical and preclinical pipeline; expectations regarding the results and analysis of data; and expectations regarding the timing, initiation, implementation and success of its planned and ongoing clinical trials for vidutolimod (CMP-001), and the benefits and related implications of current and future partnerships and/or collaborations. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. These forward-looking statements are subject to risks and uncertainties, including those related to the development of our product candidate, including any delays in our ongoing or planned preclinical or clinical trials, the results from clinical trials, including the fact that positive results from a trial may not necessarily be predictive of the results of future or ongoing clinical trials, the impact of the ongoing COVID-19 pandemic on our business, operations, clinical supply and plans, the risks inherent in the drug development process, the risks regarding the accuracy of our estimates of expenses and timing of development, our capital requirements and the need for additional financing, and obtaining, maintaining and protecting our intellectual property. These and additional risks are discussed in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ending December 31, 2020, as filed with the Securities and Exchange Commission pursuant to Rule 424(b) under the Securities Act 1933, as amended, which is available on the Securities and Exchange Commission’s website at www.sec.gov, and as well as discussions of potential risks, uncertainties and other important factors in Checkmate’s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Checkmate undertakes no duty to update this information unless required by law.



Investor Contact
Rob Dolski
Chief Financial Officer
[email protected]

Media Contact
Karen Sharma
MacDougall
781-235-3060
[email protected]

Arch Biopartners Completes Enrollment in Phase II Trial of Metablok (LSALT Peptide) in Hospitalized Patients with COVID-19

TORONTO, May 04, 2021 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today announced it has completed enrollment for its Phase II study of Metablok (LSALT Peptide), targeting acute lung injury and acute kidney injury caused by inflammation in patients with severe cases of COVID-19. The Company expects to announce results in July 2021.

A total of 65 patients were randomized into the double-blind, placebo-controlled trial and 61 of these patients received at least one treatment dose.

“We would like to thank all of the patients and their families, as well as our clinical site teams in Canada, Turkey and the USA, for helping us achieve our patient enrollment target for this Phase II trial,” said Richard Muruve, CEO of Arch Biopartners.

About the Phase II trial for LSALT Peptide

The Phase II trial is an international, multicenter, randomized, double-blind, placebo-controlled, proof of concept study of LSALT peptide (Metablok) as prevention of organ inflammation known to trigger acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI) in patients infected with SARS-CoV-2 (COVID-19) or new variants of the virus. ARDS is the leading cause of death in COVID-infected patients. AKI has been observed in approximately 35% of patients admitted to hospital with COVID-19 and is also a leading cause of mortality.1

The composite primary endpoint of the Phase II trial reflects the severe effects often experienced by hospitalized COVID-19 patients and deemed appropriate for LSALT peptide’s novel mechanism of action in blocking consequential inflammation in the lungs, kidneys, and other organs.

Additional information about the Phase II trial can be found at:

https://clinicaltrials.gov/ct2/show/NCT04402957

The Phase II results will be used to design the Phase III program, including greater patient numbers, to more fully evaluate efficacy and safety in hospitalized patients at risk to inflammation in the lungs, kidneys or liver.

About COVID-19

COVID-19 is the disease caused by the novel coronavirus SARS-CoV-2 that emerged in China in late 2019. Severe complications from COVID-19 are in large part due to excessive host immune responses to the virus that result in progressive lung inflammation and acute respiratory distress syndrome that often requires mechanical ventilation and critical care1. Patients with severe COVID-19 also experience multiple organ dysfunction including acute kidney injury, liver dysfunction, cardiac failure, and blood abnormalities. Treatment of severe COVID-19 has been primarily supportive, relying heavily on respiratory, infectious diseases, and critical care medicine.

Survival rates and health care system capacity could both be improved with new treatments that prevent the severe manifestations of COVID-19, such as worsening lung inflammation (ARDS) and AKI experienced by patients infected with SARS-CoV-22 or the many variants that have emerged globally in recent months.


1

Hirsch JS et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020
doi
:

https://doi.org/10.1016/j.kint.2020.05.006

.


2

J. S. Ayres, Sci. Adv 10.1126/sciadv.abc1518 (2020)

About Metablok (LSALT peptide) and DPEP-1

Metablok (also known as LSALT peptide) is a novel therapeutic agent and the lead DPEP-1 inhibitor in the Arch development pipeline.

A scientific team led by Arch scientists Dr. Donna Senger and Dr. Stephen Robbins first described a novel mechanism of action for organ inflammation in the journal Cell in August, 2019. In the publication, the enzyme DPEP-1 was identified for the first time as a major neutrophil adhesion receptor on the lung, liver and kidney endothelium. Their findings identified DPEP-1 as a novel therapeutic target for diseases of these organs where inflammation plays a major role.

About Arch Biopartners

Arch Biopartners Inc. is a clinical stage company focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact.  Arch is developing a pipeline of new drug candidates that inhibit inflammation in the lungs, liver and kidneys via the dipeptidase-1 (DPEP-1) pathway for multiple medical indications.

Continuing under development in the Arch portfolio are: AB569, a potential new treatment for antibiotic resistant bacterial infections in wounds and the lungs; and, ‘Borg’ peptide coatings that increase corrosion resistance and decrease bacterial biofilm on various medical grade metals and plastics.

For more information on Arch Biopartners, its technologies and other public documents Arch has filed on SEDAR, please visit www.archbiopartners.com

The Company has 61,462,302 common shares outstanding.

Forward-Looking Statements

All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change.

The science and medical contents of this release have been approved by the Company’s Chief Science Officer

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain COVID-19 (or SARS-2 Coronavirus) at this time

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release



For more information, please contact:

Richard Muruve
Chief Executive Officer
Arch Biopartners, Inc.
647-428-7031
[email protected]

Malibu Boats, Inc. Announces Record Third Quarter Fiscal 2021 Results

Fiscal Third Quarter 2021 Highlights Compared to Fiscal Third Quarter 2020:

  • Net sales increased 49.8% to $273.2 million
  • Unit volume increased 36.6%
  • Gross profit increased 57.1% to $72.0 million
  • Net income increased 47.2% to $35.1 million
  • Adjusted EBITDA increased 56.7% to $57.0 million
  • Net income available to Class A Common Stock per share (diluted) increased 47.7% to $1.61 per share
  • Adjusted fully distributed net income per share increased 61.1% to $1.82 per share on a fully distributed weighted average share count of 21.7 million shares of Class A Common Stock

LOUDON, Tenn., May 04, 2021 (GLOBE NEWSWIRE) — Malibu Boats, Inc. (Nasdaq: MBUU) today announced its financial results for the third quarter ended March 31, 2021.

“We delivered a record-setting third quarter and the best quarter in company history from both a revenue and earnings perspective. This would have been true even without the addition of Maverick Boat Group this quarter. Our results continue to showcase the agility of our team and the strength of our flexible business model, as we posted production levels for Malibu and Pursuit that significantly exceeded historical levels and the fourth best production month ever for Maverick in March. While we have expertly navigated COVID-related supply chain constraints, disruptions resulting from the Texas storms and Kansas freeze allowed our operational excellence and versatility to shine through,” commented Jack Springer, Chief Executive Officer of Malibu Boats, Inc. “Maverick is proving to be another home run, and a perfect fit within our Malibu family of brands. We have just begun our proven process of improvement with Maverick and there are many opportunities for growth to come. Further, robust demand for our larger, newer boats has endured, supporting substantial growth and earnings power. We are optimistic that these tailwinds will remain elevated well beyond calendar year 2021.”

“As we continue to navigate through an ever-changing macro-economic landscape, I am incredibly proud of our team, who day in and day out remain laser-focused on superior execution and living the values of our Company to ensure we bring our customers industry-leading new product innovation. We look forward to leveraging these catalysts for growth as we conclude our fiscal year 2021, and continue to deliver value for our shareholders,” concluded Mr. Springer.

Fiscal Third Quarter 2021 Results (Unaudited)

  Three Months Ended March 31,   Nine Months Ended March 31,
  2021   2020   2021   2020
  (Dollars In Thousands)
Net Sales $ 273,162      $ 182,310      $ 649,793      $ 534,502   
Gross Profit $ 72,028      $ 45,849      $ 167,258      $ 125,718   
Gross Profit Margin 26.4  %   25.1  %   25.7  %   23.5  %
Net Income $ 35,135      $ 23,866      $ 79,320      $ 58,146   
Net Income Margin 12.9  %   13.1  %   12.2  %   10.8  %
Adjusted EBITDA $ 57,023      $ 36,399      $ 132,483      $ 95,464   
Adjusted EBITDA Margin 20.9  %   20.0  %   20.4  %   17.9  %

Net sales for the three months ended March 31, 2021 increased $90.9 million, or 49.8%, to $273.2 million as compared to the three months ended March 31, 2020. The increase in net sales was driven primarily by a favorable model mix in our Malibu and Cobalt segments and increased unit volumes in our Malibu and Saltwater Fishing segments due mostly to our acquisition of Maverick Boat Group on December 31, 2020. Unit volume for the three months ended March 31, 2021, increased 658 units, or 36.6%, to 2,454 units as compared to the three months ended March 31, 2020. Our unit volume increased primarily due to strong demand at our Malibu segment and additional volume in Saltwater Fishing due mostly to our acquisition of Maverick Boat Group but also supported by robust growth at Pursuit. The increase in unit volumes was constrained by the impact of severe weather on our Cobalt operations and our supply chain’s operations.

Net sales attributable to our Malibu segment increased $35.5 million, or 34.6%, to $138.0 million for the three months ended March 31, 2021, compared to the three months ended March 31, 2020. Unit volumes attributable to our Malibu segment increased 246 units for the three months ended March 31, 2021, compared to the three months ended March 31, 2020. The increase in net sales was driven primarily by increased volume, strong demand for our new, larger models and optional features.

Net sales attributable to our Cobalt segment increased $9.2 million, or 20.0%, to $55.3 million for the three months ended March 31, 2021, compared to the three months ended March 31, 2020. Unit volumes attributable to Cobalt decreased 17 units for the three months ended March 31, 2021 compared to the three months ended March 31, 2020. The increase in net sales was driven by a favorable product mix of our Cobalt models impacting net sales per unit, offset by lower volume. Our unit volumes for our Cobalt segment decreased during the three months ended March 31, 2021 as a result of weather related shutdowns of our operations and suppliers’ operations.

Net sales attributable to our Saltwater Fishing segment increased $46.2 million, or 137.2%, to $79.9 million, for the three months ended March 31, 2021, compared to the three months ended March 31, 2020. Unit volume increased 429 units for the three months ended March 31, 2021 compared to the three months ended March 31, 2020. The increase in net sales was driven primarily by the increased volumes due to the acquisition of Maverick Boat Group on December 31, 2020.

Overall consolidated net sales per unit increased 9.7% to $111,313 per unit for the three months ended March 31, 2021, compared to the three months ended March 31, 2020. Net sales per unit for our Malibu segment increased 10.6% to $99,658 per unit for the three months ended March 31, 2021, compared to the three months ended March 31, 2020, driven by higher sales of new, more expensive models and optional features. Net sales per unit for our Cobalt segment increased 24.1% to $109,615 per unit for the three months ended March 31, 2021, compared to the three months ended March 31, 2020, driven by higher sales of larger, more expensive models. Net sales per unit for our Saltwater Fishing segment decreased 42.9% to $141,396 per unit for the three months ended March 31, 2021 driven primarily by mix of models due mostly to the acquisition of Maverick Boat Group on December 31, 2020.

Cost of sales for the three months ended March 31, 2021 increased $64.7 million, or 47.4%, to $201.1 million as compared to the three months ended March 31, 2020. The increase in cost of sales was driven by higher costs related to higher net sales in all our segments. In the Malibu segment, higher per unit material and labor costs contributed $19.8 million to the increase in cost of sales and were driven by an increased mix of larger product that corresponded with higher net sales per unit. In the Cobalt segment, higher per unit material and labor costs contributed $6.3 million to the increase in cost of sales and were driven by an increased mix of larger product that corresponded with higher net sales per unit. Within our Saltwater Fishing segment, higher volumes, primarily related to the acquisition of Maverick Boat Group, drove $34.0 million of increase in cost of sales which was also modestly impacted by higher per unit costs.

Gross profit for the three months ended March 31, 2021 increased $26.2 million, or 57.1%, to $72.0 million compared to the three months ended March 31, 2020. The increase in gross profit was driven primarily by higher sales revenue with a more favorable product mix partially offset by the increased cost of sales for the reasons noted above. Gross margin for the three months ended March 31, 2021 increased 130 basis points from 25.1% to 26.4%.

Selling and marketing expenses for the three months ended March 31, 2021 increased $0.1 million, or 2.1% to $4.7 million compared to the three months ended March 31, 2020. The increase was driven primarily by incremental selling and marketing expenses from the acquisition of Maverick Boat Group offset by decreased travel and promotional events due mostly to restrictions imposed by COVID-19. As a percentage of sales, selling and marketing expenses decreased 80 basis points compared to the same period in the prior fiscal year. General and administrative expenses for the three months ended March 31, 2021, increased $8.8 million, or 90.8%, to $18.4 million as compared to the three months ended March 31, 2020 driven primarily by acquisition and integration related costs, compensation, higher legal expenses related to intellectual property litigation and incremental general and administrative expenses due to the acquisition of Maverick Boat Group. As a percentage of sales, general and administrative expenses increased 140 basis points to 6.7% for the three months ended March 31, 2021 compared to the three months ended March 31, 2020. Amortization expense for the three months ended March 31, 2021 increased $0.6 million, or 39.5% to $2.1 million compared to the three months ended March 31, 2020. The increase is due to amortization of intangibles acquired as part of the acquisition of Maverick Boat Group on December 31, 2020.

Operating income for the third quarter of fiscal year 2021 increased to $46.9 million from $30.1 million in the third quarter of fiscal year 2020. Net income for the third quarter of fiscal year 2021 increased 47.2% to $35.1 million from $23.9 million and net income margin decreased to 12.9% from 13.1% in the third quarter of fiscal year 2020. Adjusted EBITDA in the third quarter of fiscal year 2021 increased 56.7% to $57.0 million from $36.4 million, while Adjusted EBITDA margin increased to 20.9% from 20.0% in the third quarter of fiscal year 2020.

Fiscal 2021 Guidance

For the fiscal full year 2021, Malibu anticipates revenue growth approaching 38% year-over-year and Adjusted EBITDA margins of approximately 20.5%.

The Company has not provided reconciliations of guidance for Adjusted EBITDA margin, in reliance on the unreasonable efforts exception provided under Item 10(e)(1)(i)(B) of Regulation S-K. The Company is unable, without unreasonable efforts, to forecast certain items required to develop meaningful comparable GAAP financial measures. These items include acquisition and integration related expenses, costs related to the Company’s vertical integration initiatives and litigation expenses that are difficult to predict in advance in order to include in a GAAP estimate.

Conference Call and Webcast

The Company will host a webcast and conference call to discuss third quarter of fiscal year 2021 results on Tuesday, May 4, 2021, at 8:30 a.m. Eastern Time. Investors and analysts can participate on the conference call by dialing (855) 433-0928 or (484) 756-4263 and using Conference ID #7199253. Alternatively, interested parties can listen to a live webcast of the conference call by logging on to the Investor Relations section on the Company’s website at http://investors.malibuboats.com. A replay of the webcast will also be archived on the Company’s website for twelve months.

About Malibu Boats, Inc.

Based in Loudon, Tennessee, Malibu Boats, Inc. (MBUU) is a leading designer, manufacturer and marketer of a diverse range of recreational powerboats, including performance sport, sterndrive and outboard boats. Malibu Boats, Inc. is the market leader in the performance sport boat category through its Malibu and Axis boat brands, the leader in the 20’ – 40’ segment of the sterndrive boat category through its Cobalt brand, and in a leading position in the saltwater fishing boat market with its Pursuit and Cobia offshore boats and Pathfinder, Maverick, and Hewes flats and bay boat brands. A pre-eminent innovator in the powerboat industry, Malibu Boats, Inc. designs products that appeal to an expanding range of recreational boaters, fisherman and water sports enthusiasts whose passion for boating is a key component of their active lifestyles. For more information, visit www.malibuboats.com, www.axiswake.com, www.cobaltboats.com,www.pursuitboats.com, or www.maverickboatgroup.com.

Non-GAAP Financial Measures

This release includes the following financial measures defined as non-GAAP financial measures by the Securities and Exchange Commission: Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Fully Distributed Net Income and Adjusted Fully Distributed Net Income per Share. These measures have limitations as analytical tools and should not be considered as an alternative to, or more meaningful than, net income as determined in accordance with U.S. generally accepted accounting principles (“GAAP”) or as an indicator of our liquidity. Our presentation of these non-GAAP financial measures should also not be construed as an inference that our results will be unaffected by unusual or non-recurring items. Our computations of these non-GAAP financial measures may not be comparable to other similarly titled measures of other companies.

We define Adjusted EBITDA as net income before interest expense, income taxes, depreciation, amortization and non-cash, non-recurring or non-operating expenses, including certain professional fees, acquisition and integration-related expenses, non-cash compensation expense, expenses related to interruption to our engine supply during the labor strike by United Auto Workers (“UAW”) against General Motors and adjustments to our tax receivable agreement liability. We define Adjusted EBITDA Margin as Adjusted EBITDA divided by net sales. Adjusted EBITDA and Adjusted EBITDA Margin are not measures of net income as determined by GAAP. Management believes Adjusted EBITDA and Adjusted EBITDA Margin allow investors to evaluate our operating performance and compare our results of operations from period to period on a consistent basis by excluding items that management does not believe are indicative of core operating performance. Management uses Adjusted EBITDA to assist in highlighting trends in our operating results without regard to our financing methods, capital structure, and non-recurring or non-operating expenses. We exclude the items listed above from net income in arriving at Adjusted EBITDA because these amounts can vary substantially from company to company within our industry depending upon accounting methods and book values of assets, capital structures, the methods by which assets were acquired and other factors.

Certain items excluded from Adjusted EBITDA are significant components in understanding and assessing a company’s financial performance, such as a company’s cost of capital and tax structure, as well as the historical costs of depreciable assets.

We define Adjusted Fully Distributed Net Income as net income attributable to Malibu Boats, Inc. (i) excluding income tax expense, (ii) excluding the effect of non-recurring or non-cash items, (iii) assuming the exchange of all LLC units into shares of Class A Common Stock, which results in the elimination of non-controlling interest in Malibu Boats Holdings, LLC (the “LLC”), and (iv) reflecting an adjustment for income tax expense on fully distributed net income before income taxes at our estimated effective income tax rate. Adjusted Fully Distributed Net Income is a non-GAAP financial measure because it represents net income attributable to Malibu Boats, Inc., before non-recurring or non-cash items and the effects of non-controlling interests in the LLC. We use Adjusted Fully Distributed Net Income to facilitate a comparison of our operating performance on a consistent basis from period to period that, when viewed in combination with our results prepared in accordance with GAAP, provides a more complete understanding of factors and trends affecting our business than GAAP measures alone. We believe Adjusted Fully Distributed Net Income assists our board of directors, management and investors in comparing our net income on a consistent basis from period to period because it removes non-cash or non-recurring items, and eliminates the variability of non-controlling interest as a result of member owner exchanges of LLC units into shares of Class A Common Stock. In addition, because Adjusted Fully Distributed Net Income is susceptible to varying calculations, the Adjusted Fully Distributed Net Income measures, as presented in this release, may differ from and may, therefore, not be comparable to similarly titled measures used by other companies.

A reconciliation of our net income as determined in accordance with GAAP to Adjusted EBITDA and the numerator and denominator for our net income available to Class A Common Stock per share to Adjusted Fully Distributed Net Income per share of Class A Common Stock is provided under “Reconciliation of Non-GAAP Financial Measures”.

Cautionary Statement Concerning Forward Looking Statements

This press release includes forward-looking statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Forward-looking statements can be identified by such words and phrases as “believes,” “anticipates,” “expects,” “intends,” “estimates,” “may,” “will,” “should,” “continue” and similar expressions, comparable terminology or the negative thereof, and includes statements in this press release regarding our expectations for fiscal year 2021; our expectations for opportunities for growth and demand for our products, including beyond calendar year 2021; and our ability to continue to deliver value for our shareholders.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, including, but not limited to: the effects of the COVID-19 pandemic on us; general industry, economic and business conditions; our ability to grow our business through acquisitions and integrate such acquisitions to fully realize their expected benefits, including our recent acquisition of Maverick Boat Group; our reliance on our network of independent dealers and increasing competition for dealers; our large fixed cost base; intense competition within our industry; increased consumer preference for used boats or the supply of new boats by competitors in excess of demand; the successful introduction of new products; our ability to execute our manufacturing strategy successfully; the success of our engines integration strategy; and other factors affecting us detailed from time to time in our filings with the Securities and Exchange Commission. Many of these risks and uncertainties are outside our control, and there may be other risks and uncertainties which we do not currently anticipate because they relate to events and depend on circumstances that may or may not occur in the future. Although we believe that the expectations reflected in any forward-looking statements are based on reasonable assumptions at the time made, we can give no assurance that our expectations will be achieved. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation (and we expressly disclaim any obligation) to update or supplement any forward-looking statements that may become untrue because of subsequent events, whether because of new information, future events, changes in assumptions or otherwise. Comparison of results for current and prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data.

Malibu Boats, Inc.

Wayne Wilson
Chief Financial Officer
(865) 458-5478
[email protected]

MALIBU BOATS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited)

(In thousands, except share and per share data)

  Three Months Ended 

March 31,
  Nine Months Ended 

March 31,
  2021   2020   2021   2020
Net sales $ 273,162     $ 182,310     $ 649,793     $ 534,502  
Cost of sales 201,134     136,461     482,535     408,784  
Gross profit 72,028     45,849     167,258     125,718  
Operating expenses:              
Selling and marketing 4,667     4,572     12,280     14,304  
General and administrative 18,402     9,643     45,092     30,389  
Amortization 2,094     1,501     5,142     4,622  
Operating income 46,865     30,133     104,744     76,403  
Other (income) expense, net:              
Other income, net (7 )   (1,660 )   (29 )   (1,679 )
Interest expense 796     940     1,797     3,064  
Other (income) expense, net 789     (720 )   1,768     1,385  
Income before provision for income taxes 46,076     30,853     102,976     75,018  
Provision for income taxes 10,941     6,987     23,656     16,872  
Net income 35,135     23,866     79,320     58,146  
Net income attributable to non-controlling interest 1,339     1,088     3,206     2,787  
Net income attributable to Malibu Boats, Inc. $ 33,796     $ 22,778     $ 76,114     $ 55,359  
               
Comprehensive income:              
Net income $ 35,135     $ 23,866     $ 79,320     $ 58,146  
Other comprehensive income (loss):              
Change in cumulative translation adjustment (262 )   (2,078 )   1,790     (2,086 )
Other comprehensive income (loss) (262 )   (2,078 )   1,790     (2,086 )
Comprehensive income 34,873     21,788     81,110     56,060  
Less: comprehensive income attributable to non-controlling interest 1,329     993     3,282     2,692  
Comprehensive income attributable to Malibu Boats, Inc. $ 33,544     $ 20,795     $ 77,828     $ 53,368  
               
Weighted average shares outstanding used in computing net income per share:              
Basic 20,799,405     20,630,741     20,722,339     20,684,034  
Diluted 21,032,360     20,775,108     20,939,927     20,827,958  
Net income available to Class A Common Stock per share:              
Basic $ 1.62     $ 1.11     $ 3.67     $ 2.68  
Diluted $ 1.61     $ 1.09     $ 3.63     $ 2.66  





MALIBU BOATS, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets (Unaudited)

(In thousands, except share and per share data)

  March 31, 2021   June 30, 2020
Assets      
Current assets      
Cash $ 42,993     $ 33,787  
Trade receivables, net 36,918     13,767  
Inventories, net 115,712     72,946  
Prepaid expenses and other current assets 5,279     3,954  
Total current assets 200,902     124,454  
Property, plant and equipment, net 123,988     94,310  
Goodwill 101,126     51,273  
Other intangible assets, net 237,493     139,892  
Deferred tax asset 49,208     52,935  
Other assets 17,549     14,482  
Total assets $ 730,266     $ 477,346  
Liabilities      
Current liabilities      
Current maturities of long-term obligations $ 4,250     $  
Accounts payable 40,596     15,846  
Accrued expenses 75,606     50,485  
Income taxes and tax distribution payable 4,585     243  
Payable pursuant to tax receivable agreement, current portion 3,589     3,589  
Total current liabilities 128,626     70,163  
Deferred tax liabilities 28,177     14  
Other liabilities 20,518     16,727  
Payable pursuant to tax receivable agreement, less current portion 48,150     46,076  
Long-term debt 159,190     82,839  
Total liabilities 384,661     215,819  
       
Stockholders’ Equity      
Class A Common Stock, par value $0.01 per share, 100,000,000 shares authorized; 20,844,019 shares issued and outstanding as of March 31, 2021; 20,595,969 issued and outstanding as of June 30, 2020 207     204  
Class B Common Stock, par value $0.01 per share, 25,000,000 shares authorized; 11 shares issued and outstanding as of March 31, 2021; 15 shares issued and outstanding as of June 30, 2020      
Preferred Stock, par value $0.01 per share; 25,000,000 shares authorized; no shares issued and outstanding as of March 31, 2021 and June 30, 2020      
Additional paid in capital 109,692     103,797  
Accumulated other comprehensive loss (1,342 )   (3,132 )
Accumulated earnings 229,825     153,711  
Total stockholders’ equity attributable to Malibu Boats, Inc. 338,382     254,580  
Non-controlling interest 7,223     6,947  
Total stockholders’ equity 345,605     261,527  
Total liabilities and stockholders’ equity $ 730,266     $ 477,346  





MALIBU BOATS, INC. AND SUBSIDIARIES

Reconciliation of Non-GAAP Financial Measures

Reconciliation of Net Income to Non-GAAP Adjusted EBITDA (Unaudited):

The following table sets forth a reconciliation of net income as determined in accordance with GAAP to Adjusted EBITDA and presentation of Net Income Margin and Adjusted EBITDA Margin for the periods indicated (dollars in thousands):

  Three Months Ended March 31,   Nine Months Ended March 31,
  2021   2020   2021   2020
Net income $ 35,135     $ 23,866     $ 79,320     $ 58,146  
Provision for income taxes 10,941     6,987     23,656     16,872  
Interest expense 796     940     1,797     3,064  
Depreciation 4,130     2,938     11,215     9,040  
Amortization 2,094     1,501     5,142     4,622  
Professional fees 1 948     124     3,186     500  
Acquisition and integration related expenses 2 1,530         4,107      
Stock-based compensation expense 3 1,449     816     4,060     2,306  
UAW strike impact 4     877         2,564  
Adjustments to tax receivable agreement liability 5     (1,650 )       (1,650 )
Adjusted EBITDA $ 57,023     $ 36,399     $ 132,483     $ 95,464  
Net Sales $ 273,162     $ 182,310     $ 649,793     $ 534,502  
Net Income Margin 6 12.9  %   13.1  %   12.2  %   10.8  %
Adjusted EBITDA Margin 6 20.9  %   20.0  %   20.4  %   17.9  %

(1 ) Represents legal and advisory fees related to our litigation with Skier’s Choice, Inc.
(2 ) For the three months and nine months ended March 31, 2021, represents legal and advisory fees incurred in connection with our acquisition of Maverick Boat Group on December 31, 2020. Integration related expenses for the three and nine months ended March 31, 2021 include post-acquisition adjustments to cost of goods sold of $0.9 million for the fair value step up of inventory acquired from Maverick Boat Group, which was sold during the third quarter of fiscal 2021.
(3 ) Represents equity-based incentives awarded to key employees under the Malibu Boats, Inc. Long-Term Incentive Plan and profit interests issued under the previously existing limited liability company agreement of the LLC.
(4 ) For the three and nine months ended March 31, 2020, represents costs incurred in connection with interruption to our engine supply during the UAW strike against General Motors. We purchase engines from General Motors LLC that we then prepare for marine use for our Malibu and Axis boats. During the UAW strike, General Motors suspended delivery of engine blocks to us and we incurred costs by entering into purchase agreements with two suppliers for additional engines to supplement our inventory of engine blocks for Malibu and Axis boats.
(5 ) For the three and nine months ended March 31, 2020 we recognized other income from an adjustment in our tax receivable agreement liability as a result of a decrease in the estimated tax rate used in computing our future tax obligations and in turn, a decrease in the future tax benefit we expect to pay under our tax receivable agreement with pre-IPO owners.
(6 ) We calculate net income margin as net income divided by net sales and we define adjusted EBITDA margin as adjusted EBITDA divided by net sales.





Reconciliation of Non-GAAP Adjusted Fully Distributed Net Income (Unaudited):

The following table shows the reconciliation of the numerator and denominator for net income available to Class A Common Stock per share to Adjusted Fully Distributed Net Income per Share of Class A Common Stock for the periods presented (in thousands except share and per share data):

  Three Months Ended March 31,   Nine Months Ended March 31,
  2021   2020   2021   2020
Reconciliation of numerator for net income available to Class A Common Stock per share to Adjusted Fully Distributed Net Income per Share of Class A Common Stock:              
Net income attributable to Malibu Boats, Inc. $ 33,796     $ 22,778     $ 76,114     $ 55,359  
Provision for income taxes 10,941     6,987     23,656     16,872  
Professional fees 1 948     124     3,186     500  
Acquisition and integration related expenses 2 3,170     1,053     7,894     3,200  
Fair market value adjustment for interest rate swap 3     10         68  
Stock-based compensation expense 4 1,449     816     4,060     2,306  
UAW strike impact 5     877         2,564  
Adjustments to tax receivable agreement liability 6     (1,650 )       (1,650 )
Net income attributable to non-controlling interest 7 1,339     1,088     3,206     2,787  
Fully distributed net income before income taxes 51,643     32,083     118,116     82,006  
Income tax expense on fully distributed income before income taxes 8 12,187     7,539     27,875     19,271  
Adjusted fully distributed net income $ 39,456     $ 24,544     $ 90,241     $ 62,735  

  Three Months Ended March 31,   Nine Months Ended March 31,
  2021   2020   2021   2020
Reconciliation of denominator for net income available to Class A Common Stock per share to Adjusted Fully Distributed Net Income per Share of Class A Common Stock:              
Weighted average shares outstanding of Class A Common Stock used for basic net income per share:   20,799,405       20,630,741       20,722,339       20,684,034  
Adjustments to weighted average shares of Class A Common Stock:              
Weighted-average LLC units held by non-controlling unit holders 9   643,292       805,822       686,407       822,042  
Weighted-average unvested restricted stock awards issued to management 10   231,165       181,015       206,406       146,905  
Adjusted weighted average shares of Class A Common Stock outstanding used in computing Adjusted Fully Distributed Net Income per Share of Class A Common Stock:   21,673,862       21,617,578       21,615,152       21,652,981  

The following table shows the reconciliation of net income available to Class A Common Stock per share to Adjusted Fully Distributed Net Income per Share of Class A Common Stock for the periods presented:

  Three Months Ended March 31,   Nine Months Ended March 31,
  2021   2020   2021   2020
Net income available to Class A Common Stock per share $ 1.62     $ 1.11     $ 3.67     $ 2.68  
Impact of adjustments:              
Provision for income taxes 0.53     0.34     1.14     0.82  
Professional fees 1 0.04         0.15     0.02  
Acquisition and integration related expenses 2 0.15     0.05     0.38     0.15  
Fair market value adjustment for interest rate swap 3              
Stock-based compensation expense 4 0.07     0.04     0.20     0.11  
UAW strike impact 5     0.04         0.12  
Adjustment to tax receivable agreement liability 6     (0.08 )       (0.08 )
Net income attributable to non-controlling interest 7 0.06     0.05     0.15     0.13  
Fully distributed net income per share before income taxes 2.47     1.55     5.69     3.95  
Impact of income tax expense on fully distributed income before income taxes 8 (0.59 )   (0.37 )   (1.34 )   (0.94 )
Impact of increased share count 11 (0.06 )   (0.05 )   (0.18 )   (0.12 )
Adjusted Fully Distributed Net Income per Share of Class A Common Stock $ 1.82     $ 1.13     $ 4.17     $ 2.89  

(1 ) Represents legal and advisory fees related to our litigation with Skier’s Choice, Inc.
(2 ) For the three and nine months ended March 31, 2021, represents legal and advisory fees incurred in connection with the acquisition of Maverick Boat Group and amortization of intangibles acquired in connection with the acquisition of Maverick Boat Group, Pursuit and Cobalt. Integration related expenses for the three and nine months ended March 31, 2021 include post-acquisition adjustments to cost of goods sold of $0.9 million for the fair value step up of inventory acquired from Maverick Boat Group, which was sold during the second quarter of fiscal 2021. For the three and nine months ended March 31, 2020, represents amortization of intangibles acquired in connection with the acquisition of Pursuit and Cobalt.
(3 ) Represents the change in the fair value of our interest rate swap entered into on July 1, 2015. The swap matured on March 31, 2020.
(4 ) Represents equity-based incentives awarded to certain of our employees under the Malibu Boats, Inc. Long-Term Incentive Plan and profit interests issued under the previously existing limited liability company agreement of the LLC.
(5 ) For the three and nine months ended March 31, 2020, represents costs incurred in connection with interruption to our engine supply during the UAW strike against General Motors. We purchase engines from General Motors LLC that we then prepare for marine use for our Malibu and Axis boats. During the UAW strike, General Motors suspended delivery of engine blocks to us and we incurred costs by entering into purchase agreements with two suppliers for additional engines to supplement our inventory of engine blocks for Malibu and Axis boats.
(6 ) For the three and nine months ended March 31, 2020, we recognized other income from an adjustment in our tax receivable agreement liability as a result of a decrease in the estimated tax rate used in computing our future tax obligations and in turn, a decrease in the future tax benefit we expect to pay under our tax receivable agreement with pre-IPO owners.
(7 ) Reflects the elimination of the non-controlling interest in the LLC as if all LLC members had fully exchanged their LLC Units for shares of Class A Common Stock.
(8 ) Reflects income tax expense at an estimated normalized annual effective income tax rate of 23.6% and 23.5% of income before income taxes for the three and nine month periods ended March 31, 2021 and 2020, respectively, assuming the conversion of all LLC Units into shares of Class A Common Stock. The estimated normalized annual effective income tax rate for fiscal year 2021 is based on the federal statutory rate plus a blended state rate adjusted for the research and development tax credit, the foreign derived intangible income deduction, and foreign income taxes attributable to our Australian subsidiary.
(9 ) Represents the weighted average shares outstanding of LLC Units held by non-controlling interests assuming they were exchanged into Class A Common Stock on a one-for-one basis.
(10 ) Represents the weighted average unvested restricted stock awards included in outstanding shares during the applicable period that were convertible into Class A Common Stock and granted to members of management.
(11 ) Reflects impact of increased share counts assuming the exchange of all weighted average shares outstanding of LLC Units into shares of Class A Common Stock and the conversion of all weighted average unvested restricted stock awards included in outstanding shares granted to members of management.



Cerevel Therapeutics Announces the Appointment of Scott M. Akamine as Chief Legal Officer

CAMBRIDGE, Mass., May 04, 2021 (GLOBE NEWSWIRE) — Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Scott M. Akamine as chief legal officer, effective May 24, 2021. An accomplished legal executive, Mr. Akamine brings significant healthcare and biopharmaceutical experience to the role. He joins Cerevel from AEON Biopharma, Inc., a privately-held biopharmaceutical company, where he served as general counsel and corporate secretary, overseeing legal and certain administrative functions, including business development, corporate governance, intellectual property, and compliance. 

“Scott has an impressive track record as a legal executive and brings to Cerevel extensive experience guiding companies through periods of significant growth,” said Tony Coles, M.D., chairperson and chief executive officer of Cerevel Therapeutics. “His legal acumen, together with a proven ability to drive key business priorities, will be essential for Cerevel as we continue on our journey to bring new, effective therapies to those suffering from neuroscience diseases.”

“I am honored to join Cerevel and have the opportunity to make a tremendous difference in the lives of millions of patients facing Parkinson’s disease, epilepsy, schizophrenia, and other neuroscience diseases,” said Mr. Akamine. “I look forward to joining this outstanding team and supporting Cerevel as it seeks to transform what is possible in neuroscience.”

About Scott M. Akamine

Scott is an accomplished biopharmaceutical legal executive with experience guiding growth strategies through complex competitive, legal, and regulatory landscapes. He served most recently as general counsel and corporate secretary of AEON Biopharma, Inc., a privately-held biopharmaceutical company, overseeing legal and certain administrative functions, including business development, corporate governance, intellectual property, and compliance. Prior to AEON, Scott was the associate general counsel and interim general counsel at CoreLogic, Inc. and general counsel and corporate secretary at Incipio, LLC. He also held legal roles of escalating responsibility at Allergan, Inc. until the company was acquired by Actavis plc. 

Scott began his legal career as a corporate attorney at Latham & Watkins. He earned his B.A. from Chapman University and his J.D. from Pepperdine University School of Law, where he graduated with honors.

About Cerevel Therapeutics

Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling diseases with a targeted approach to neuroscience that combines expertise in neurocircuitry with a focus on receptor selectivity. Cerevel Therapeutics has a diversified pipeline comprising five clinical-stage investigational therapies and several pre-clinical compounds with the potential to treat a range of neuroscience diseases, including Parkinson’s, epilepsy, schizophrenia, and substance use disorder. Headquartered in Cambridge, Mass., Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations, or potential acquisitions. For more information, visit www.cerevel.com.

Special Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements about our potential to introduce new therapies to patients and the potential attributes and benefits of our product candidates. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties, including,
those under the heading “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on March 24, 2021 and our subsequent SEC filings. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Media Contact:

Kate Contreras
W2O/Real Chemistry
[email protected]

Investor Contact:

Matthew Calistri
Cerevel Therapeutics
[email protected] 



VAST Data Triples Valuation in One Year to $3.7 Billion

Tiger Global Management Leads $83M Series D, Confirming VAST’s Best-In-Class Business Performance

NEW YORK, May 04, 2021 (GLOBE NEWSWIRE) — VAST Data, the storage software company breaking decades-old tradeoffs, today announced $83 million in Series D funding, led by Tiger Global Management, at a post-money valuation of $3.7 billion – a tripling of the company’s valuation since April 2020. The round features strong participation from NVIDIA and several other existing investors, and is driven by VAST’s unique combination of rapid customer adoption and positive cash flow. The funds add to VAST’s Series B and Series C investments to create a balance sheet that is $230M strong, positioning VAST as the next great independent infrastructure company that is poised to disrupt and transform cloud and AI data centers globally.

The valuation comes as VAST recently reported record-breaking results and rapid customer growth throughout its first two years of operation. VAST ended its second year at nearly $100M of annualized software run rate, having quadrupled its software business year over year, while also achieving cash flow positivity. These results will be catalyzed in 2021 and beyond by VAST’s new software consumption model called Gemini, which disaggregates the business of hardware and software and provides customers with additional commercial advantages to further the adoption of Universal Storage.

Key success metrics that influenced the Series D include:

  • Over 300% Customer Revenue Expansion: VAST customers make significant initial investments at an average of $1M, and have subsequently scaled these investments significantly in a very short time. On average, VAST has expanded its net revenue within existing customers by 328%. VAST now has several private and public sector customers who have invested over $10M in Universal Storage.

  • Hypergrowth with Cash Flow Positivity: Just as VAST has broken key architectural tradeoffs to transform customers’ relationship with data, the VAST Data business model has uniquely combined breakthrough levels of revenue growth with unparalleled cash efficiency. When combining an average selling price of $1M and VAST’s net revenue expansion with customers, the VAST go-to-market model results in higher revenue with fewer resources. This enables the company to focus on growth and serving its customers indefinitely without concern for additional capital raises.

  • A Foundation for the Next Generation of AI Computing: Fast access to vast reserves of data is the cornerstone of the modern computing agenda. VAST Data has established a vision for its software that extends well beyond the classical boundaries of data storage and will redefine how organizations compute, infer and train AI models. Beyond the era of digital transformation, VAST’s innovative platform will usher in the era of natural data analysis.

“The pioneering and inventive spirit of our team influences every aspect of our product and business and has redefined how successful businesses can be built,” said Renen Hallak, Founder and CEO of VAST Data. “We are humbled by today’s validation from Tiger and NVIDIA. It is evidence of our accomplishments to date and serves as a launchpad for the opportunity ahead of us.”

“VAST Data’s innovation engine has resulted in a breakout business story that speaks for itself,” said John Curtius, Partner at Tiger Global Management. “We’re excited to partner with VAST as they transform the value that organizations extract from their data, and we see incredible potential as enterprises embrace data-driven AI computing across every facet of their business.”

To learn more, visit the VAST Data blog to read Breaking the Mold (by Jeff Denworth, CMO).

About VAST Data

Headquartered in New York City, VAST Data’s managed storage software unlocks the value of data and modernizes data centers in preparation for the era of AI computing. VAST delivers real-time performance to all data and overcomes the historic cost barriers to building all-flash data centers. Since its launch in February 2019, VAST has become the fastest-selling infrastructure startup in history.

About Tiger Global Management

Tiger Global Management is a leading global technology investment firm with over $60 billion under management. The firm focuses on private and public companies in the internet, software, and financial technology sectors. Since 2001, Tiger Global has invested in hundreds of companies across more than 30 countries, including investments ranging from Series A to pre-IPO. The firm aims to partner with dynamic entrepreneurs operating market-leading companies in its core focus areas. Tiger Global’s investments have included JD.com, UiPath, Stripe, Databricks, Bytedance, Snowflake, Facebook, Alibaba, Procore, Chime, Blend, Peloton, Attentive, LinkedIn, Flipkart, and Toast.

VAST Data Resources

  • Vastdata.com
  • Twitter: twitter.com/VAST_Data
  • LinkedIn: linkedin.com/company/vast-data/
  • YouTube: youtube.com/VASTData
  • Careers @ VAST Data: vastdata.com/careers

Media Contact

Highwire PR for VAST Data
[email protected]